These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33533694)

  • 21. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
    Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
    Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
    [No Abstract]   [Full Text] [Related]  

  • 22. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
    Kuo FC
    Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next generation sequencing in hematolymphoid neoplasia.
    Kuo FC
    Semin Hematol; 2019 Jan; 56(1):2-6. PubMed ID: 30573040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.
    Sánchez R; Ayala R; Martínez-López J
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies.
    Fukuhara S; Oshikawa-Kumade Y; Kogure Y; Shingaki S; Kariyazono H; Kikukawa Y; Koya J; Saito Y; Tabata M; Yoshifuji K; Mizuno K; Miyagi-Maeshima A; Matsushita H; Sugiyama M; Ogawa C; Inamoto Y; Fukuda T; Sugano M; Yamauchi N; Minami Y; Hirata M; Yoshida T; Kohno T; Kohsaka S; Mano H; Shiraishi Y; Ogawa S; Izutsu K; Kataoka K
    Cancer Sci; 2022 Aug; 113(8):2763-2777. PubMed ID: 35579198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
    Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
    Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
    Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
    Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing.
    Ptashkin RN; Ewalt MD; Jayakumaran G; Kiecka I; Bowman AS; Yao J; Casanova J; Lin YD; Petrova-Drus K; Mohanty AS; Bacares R; Benhamida J; Rana S; Razumova A; Vanderbilt C; Balakrishnan Rema A; Rijo I; Son-Garcia J; de Bruijn I; Zhu M; Lachhander S; Wang W; Haque MS; Seshan VE; Wang J; Liu Y; Nafa K; Borsu L; Zhang Y; Aypar U; Suehnholz SP; Chakravarty D; Park JH; Abdel-Wahab O; Mato AR; Xiao W; Roshal M; Yabe M; Batlevi CL; Giralt S; Salles G; Rampal R; Tallman M; Stein EM; Younes A; Levine RL; Perales MA; van den Brink MRM; Dogan A; Ladanyi M; Berger MF; Brannon AR; Benayed R; Zehir A; Arcila ME
    Nat Commun; 2023 Oct; 14(1):6895. PubMed ID: 37898613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.
    Bregni G; Sticca T; Camera S; Akin Telli T; Craciun L; Trevisi E; Pretta A; Kehagias P; Leduc S; Senti C; Deleporte A; Vandeputte C; Saad ED; Kerger J; Gil T; Piccart-Gebhart M; Awada A; Demetter P; Larsimont D; Hendlisz A; Aftimos P; Sclafani F
    Acta Oncol; 2020 Dec; 59(12):1438-1446. PubMed ID: 32820683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
    Kohlmann A; Bacher U; Schnittger S; Haferlach T
    Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Interpretation of Sequence Variants in Myeloid Neoplasms.
    Hanbazazh M; Harada S; Reddy V; Mackinnon AC; Harbi D; Morlote D
    Am J Clin Pathol; 2021 Oct; 156(5):728-748. PubMed ID: 34155503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Next-generation sequencing and its application in acute myeloid leukemia and myelodysplastic syndrome].
    Gu SC; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1545-9. PubMed ID: 22169322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategy.
    Shen W; Szankasi P; Sederberg M; Schumacher J; Frizzell KA; Gee EP; Patel JL; South ST; Xu X; Kelley TW
    Br J Haematol; 2016 Apr; 173(1):49-58. PubMed ID: 26728869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
    Vantyghem S; Peterlin P; Thépot S; Ménard A; Dubruille V; Debord C; Guillaume T; Garnier A; Le Bourgeois A; Wuilleme S; Godon C; Theisen O; Eveillard M; Delaunay J; Maisonneuve H; Morineau N; Villemagne B; Vigouroux S; Subiger F; Lestang E; Loirat M; Parcelier A; Godmer P; Mercier M; Trebouet A; Luque Paz D; Le Calloch R; Le Clech L; Bossard C; Moreau A; Ugo V; Hunault M; Moreau P; Le Gouill S; Chevallier P; Béné MC; Le Bris Y
    Haematologica; 2021 Mar; 106(3):701-707. PubMed ID: 32241844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
    Miyamoto K; Minami Y
    Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Necessity of Genetic Examination in Treatment for Hematological Malignancies].
    Kiyoi H
    Rinsho Byori; 2015 Mar; 63(3):369-76. PubMed ID: 26524860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.